Abstract
Development of molecular signature and CMap analysis. A, A molecular signature was established through the integration of significant changes between MIBC and NMIBC derived from multiomics data (proteomics and transcriptomics), further enriched with literature-mined data. B, The signature was randomly divided into 10 sets of molecular features and used to query the CMap to predict drugs/compounds affecting the disease’s molecular signature. C, The significant negative enrichment scores for the drugs selected for subsequent in vitro investigations are depicted. GEO, Gene Expression Omnibus; MIBC, muscle-invasive bladder cancer; NMIBC, non muscle-invasive bladder cancer.